Is Stryker Stock a Good Investment?
Stryker Corporation (NYSE: SYK) is a leading global medical technology company. The company offers a diverse range of products and services, including surgical equipment, implants, medical imaging systems, and healthcare software.
Stryker has a long history of innovation and growth. The company was founded in 1941, and it has since grown to become one of the largest medical technology companies in the world. Stryker's products are used in hospitals and clinics around the world, and the company has a strong reputation for quality and innovation.
Stryker Stock Price History
Stryker's stock price has performed well over the past several years. The stock has outperformed the S&P 500 index, and it has also outperformed many of its peers in the medical technology industry.
In 2021, Stryker's stock price rose by over 20%. The stock has continued to rise in 2022, and it is currently trading at around $150 per share.
Factors Affecting Stryker's Stock Price
Several factors could affect Stryker's stock price in the future. These factors include:
Is Stryker Stock a Good Investment?
Whether or not Stryker stock is a good investment depends on several factors, including the investor's risk tolerance and investment goals. However, Stryker has a long history of innovation and growth, and the company is well-positioned to continue to grow in the future.
Here are some of the reasons why Stryker stock could be a good investment:
Common Mistakes to Avoid
Several common mistakes investors should avoid when investing in Stryker stock. These mistakes include:
Conclusion
Stryker is a leading global medical technology company with a long history of innovation and growth. The company's stock has performed well over the past several years, and it is well-positioned to continue to grow in the future. However, investing in stocks is always risky, and investors should carefully consider their risk tolerance and investment goals before investing in Stryker stock.
Financial Metric | Value |
---|---|
Market Cap | $54.3 billion |
Revenue (2021) | $15.4 billion |
Net Income (2021) | $2.3 billion |
EPS (2021) | $8.62 |
P/E Ratio | 17.5 |
Key Statistic | Value |
---|---|
Number of Employees | 43,000 |
Number of Products | 10,000+ |
Number of Customers | 1 million+ |
Global Reach | 100+ countries |
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-01-03 | $130.00 | $132.00 | $129.00 | $131.00 | 2,321,000 |
2022-01-04 | $131.00 | $133.00 | $130.00 | $132.00 | 2,054,000 |
2022-01-05 | $132.00 | $134.00 | $131.00 | $133.00 | 1,897,000 |
2022-01-06 | $133.00 | $135.00 | $132.00 | $134.00 | 1,769,000 |
2022-01-07 | $134.00 | $136.00 | $133.00 | $135.00 | 1,692,000 |
Forecast Period | Price Target |
---|---|
12 Months | $155.00 |
24 Months | $170.00 |
36 Months | $185.00 |
Analyst Firm | Recommendation | Price Target |
---|---|---|
Citigroup | Buy | $155.00 |
Goldman Sachs | Neutral | $150.00 |
Morgan Stanley | Overweight | $160.00 |
Date | Dividend |
---|---|
2022-03-10 | $0.72 |
2021-09-10 | $0.68 |
2021-03-10 | $0.64 |
2020-09-10 | $0.60 |
2020-03-10 | $0.56 |
2024-11-17 01:53:44 UTC
2024-11-18 01:53:44 UTC
2024-11-19 01:53:51 UTC
2024-08-01 02:38:21 UTC
2024-07-18 07:41:36 UTC
2024-12-23 02:02:18 UTC
2024-11-16 01:53:42 UTC
2024-12-22 02:02:12 UTC
2024-12-20 02:02:07 UTC
2024-11-20 01:53:51 UTC
2024-10-08 09:53:57 UTC
2024-10-14 17:57:48 UTC
2024-12-06 16:25:19 UTC
2024-12-12 17:13:47 UTC
2024-12-18 04:38:14 UTC
2024-10-03 16:53:07 UTC
2024-10-24 11:07:37 UTC
2024-10-08 09:49:29 UTC
2025-01-06 06:15:39 UTC
2025-01-06 06:15:38 UTC
2025-01-06 06:15:38 UTC
2025-01-06 06:15:38 UTC
2025-01-06 06:15:37 UTC
2025-01-06 06:15:37 UTC
2025-01-06 06:15:33 UTC
2025-01-06 06:15:33 UTC